Literature DB >> 4004317

Oxandrolone in low dose for constitutional delay of growth and puberty in boys.

R Stanhope, C G Brook.   

Abstract

Twenty four boys with delayed pubertal growth spurt were treated with oxandrolone (2.5 mg daily) for 0.21 to 0.65 years. The mean increment of growth velocity was 4.4 cm/year during treatment, which was maintained at 3.7 cm/year after treatment. There was no significant change in height for bone age standard deviation scores.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 4004317      PMCID： PMC1777228          DOI： 10.1136/adc.60.4.379

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN： 0003-9888            Impact factor:   3.791


  3 in total

1.  Testicular volume during adolescence. Cross-sectional and longitudinal studies.

Authors:  M Zachmann; A Prader; H P Kind; H Häfliger; H Budliger
Journal:  Helv Paediatr Acta       Date:  1974-04

2.  Use of anabolic agents in treatment of short children.

Authors:  V C Kelley; R H Ruvalcaba
Journal:  Clin Endocrinol Metab       Date:  1982-03

3.  Standards from birth to maturity for height, weight, height velocity, and weight velocity: British children, 1965. II.

Authors:  J M Tanner; R H Whitehouse; M Takaishi
Journal:  Arch Dis Child       Date:  1966-12       Impact factor: 3.791
  3 in total
  17 in total

1.  Delayed puberty.

Authors:  R Stanhope; A Albanese; S Shalet
Journal:  BMJ       Date:  1992-10-03

2.  The effect of short-term growth hormone or low-dose oxandrolone treatment in boys with constitutional growth delay.

Authors:  S Loche; C Pintor; P Cambiaso; A Lampis; D Carta; R Corda; M Cappa
Journal:  J Endocrinol Invest       Date:  1991-10       Impact factor: 4.256

3.  Is testosterone therapy for boys with constitutional delay of growth and puberty associated with impaired final height and suppression of the hypothalamo-pituitary-gonadal axis?

Authors:  M Uruena; S Pantsiotou; M A Preece; R Stanhope
Journal:  Eur J Pediatr       Date:  1992-01       Impact factor: 3.183

Review 4.  Management of constitutional delay of growth and puberty.

Authors:  R Stanhope; M A Preece
Journal:  Arch Dis Child       Date:  1988-09       Impact factor: 3.791

Review 5.  Treatment of the short, sexually immature adolescent boy.

Authors:  C J Kelnar
Journal:  Arch Dis Child       Date:  1994-10       Impact factor: 3.791

6.  Biosynthetic human growth hormone treatment in the UK: an audit of current practice. Kabi Pharmacia International Growth Study.

Authors:  D A Price; D I Johnston; P R Betts; J M Buckler; M D Donaldson
Journal:  Arch Dis Child       Date:  1994-09       Impact factor: 3.791

7.  Treatment of patients with Ullrich-Turner syndrome with conventional doses of growth hormone and the combination with testosterone or oxandrolone: effect on growth, IGF-I and IGFBP-3 concentrations.

Authors:  G Haeusler; H Frisch; K Schmitt; P Blümel; E Plöchl; M Zachmann; T Waldhör
Journal:  Eur J Pediatr       Date:  1995-06       Impact factor: 3.183

8.  Does constitutional delayed puberty cause segmental disproportion and short stature?

Authors:  A Albanese; R Stanhope
Journal:  Eur J Pediatr       Date:  1993-04       Impact factor: 3.183

9.  Treatment of constitutional delay of growth and puberty with oxandrolone compared with growth hormone.

Authors:  A Buyukgebiz; P C Hindmarsh; C G Brook
Journal:  Arch Dis Child       Date:  1990-04       Impact factor: 3.791

10.  Oxandrolone in constitutional delay of growth: analysis of the growth patterns up to final stature.

Authors:  F Bassi; A S Neri; R G Gheri; D Cheli; M Serio
Journal:  J Endocrinol Invest       Date:  1993-02       Impact factor: 4.256
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.